Kevin Warsh Offered a Warning on Inflation. Here's What History Says Is Coming Next.

At the Oct. 29, 2026 FOMC meeting, the Fed held rates steady, but Chair Kevin Warsh said inflation had run above the Committee’s objective for close to six years and pledged to deliver price stability. CME FedWatch put the probability of a December rate increase at 70.9% and a January increase at 79%; the article argues further hikes are likely, while noting prior cycles produced outcomes ranging from recession and a bear market to a soft landing. It recommends avoiding richly valued, rate-sensitive growth stocks and favoring high-quality dividend stocks, while emphasizing diversification and patience.

Analysis

The key market risk is not simply another hike; it is a repricing of the expected path of real rates while equity duration is already exposed to valuation compression. But hawkish rhetoric and futures-implied hike odds are not independent confirmation: the latter may already absorb the former. A pause in tightening, or even a single hike, would not by itself establish a persistent hiking cycle. The inflation and labor data—not the chair’s language—are the near-term falsifiers. Likewise, delayed balance-sheet recommendations do not establish that quantitative tightening will accelerate soon.

For CME Group, the second-order effect is two-sided. Greater uncertainty about the policy path can support hedging activity in rates products; a clear, well-priced path or falling rate volatility could remove that tailwind. Verify product-level volume and open-interest trends before treating this as an earnings catalyst, and do not infer CME’s consolidated earnings sensitivity from policy rates alone.

Over days, hawkish repricing can pressure long-duration equities and raise rates volatility. Over 1–3 months, inflation releases and Fed communication determine whether hike expectations persist. Over 6–18 months, the larger risk is that restrictive policy slows demand and corporate earnings; dividend yield is not sufficient protection if balance sheets or earnings weaken. The article’s historical analogies do not resolve that outcome: starting valuations, inflation dynamics, and policy transmission differ.

Key Decisions for Investors

• Do not chase a broad short in growth solely on the chair’s warning. Treat a further rise in market-implied hikes as a catalyst only if incoming inflation data validate it; reverse the bearish duration view if inflation cools and expected policy rates retreat.
• Watch CME Group as a conditional relative-value long against richly valued, long-duration equities, not as a direct bet on higher rates. Prefer entry after a pullback or evidence of sustained rates-product activity; exit or reassess if rate uncertainty fades and product-level volumes weaken.
• For the next 1–3 months, monitor core inflation, labor-market releases, front-end rate pricing, and CME product-level volumes. A decline in inflation alongside falling hike expectations would falsify the near-term hawkish positioning thesis.
• Avoid treating high dividend yield as a standalone defensive screen. Prefer companies with demonstrable earnings resilience and manageable debt exposure; reduce exposure where valuation depends heavily on distant cash flows if real yields continue to rise.